Clinical trials: Patients With Tumor
Advanced Solid Tumors
Evaluation of the Safety and Efficacy of NBL-015 in Patients With Advanced Solid Tumors
This trial is an open-label, multicenter, dose-escalation and cohort-expansion Phase I clinical study in patients with advanced solid tumors.
- Trial name
- NCT05153096
- Testing
- NBL-015
- Where
- China
- Volunteers
- 410 people
- Sponsor
- NovaRock Biotherapeutics, Ltd
Hormone Receptor Positive Malignant Neoplasm of Breast
PRospective Study Of MammaPrint in Patients With an Intermediate Recurrence Score
This is a prospective study that will assess the impact of MammaPrint on chemotherapy + endocrine versus endocrine alone treatment decisions in patients with an Oncotype Intermediate Score.
- Trial name
- PROMIS (NCT01617954)
- Testing
- MammaPrint
- Where
- 53 sites in United States
- Volunteers
- 820 people
- Sponsor
- Agendia
Relapsed or Refractory Multiple Myeloma
Vorinostat (MK-0683, SAHA [Suberoylanilide Hydroxamic Acid]) + Lenalidomide + Dexamethasone in Multiple Myeloma (MM) (MK-0683-074)
The purpose of this Phase I study of vorinostat in combination with lenalidomide and dexamethasone in participants with relapsed or refractory multiple myeloma is to determine the maximum tolerated dose (MTD) as estimated by the…
- Trial name
- NCT00642954
- Testing
- Vorinostat, Lenalidomide, Dexamethasone
- Volunteers
- 31 people
- Sponsor
- Merck Sharp & Dohme LLC
Solid Tumor
A First-in-human Dose-escalation and Expansion Study With the Antibody-drug Conjugate SYD1875
This is the first-in-human study with SYD1875, an antibody-drug conjugate (ADC) comprising of a humanized IgG1 monoclonal antibody directed against the 5T4 oncofetal antigen covalently conjugated to a duocarmycin-based…
- Trial name
- NCT04202705
- Testing
- SYD1875
- Where
- 3 sites in Belgium, France
- Volunteers
- 31 people
- Sponsor
- Byondis B.V.
Malignant Glioma
Study of NPC-07 for Fluorescence-guided Resection of Malignant Gliomas
The aim of the present Phase III study is to assess the positive predictive value of NPC-07 (5-aminolevulinic acid hydrochloride) induced tissue fluorescence, safety and pharmacokinetics following a single dose of NPC-07 orally…
- Trial name
- NCT01167322
- Testing
- NPC-07 for oral administration
- Where
- 3 sites in Japan
- Volunteers
- 45 people
- Sponsor
- Nobelpharma
GVHD, Adult Acute Myeloid Leukemia
Study of US-ATG-F to Prevent Chronic Graft Versus Host Disease (GVHD)
The study objective is to compare the efficacy and safety of US-ATG-F as a supplement to standard of care prophylaxis versus standard of care prophylaxis alone in moderate to severe chronic GVHD-free survival.
- Conditions
- GVHD, Adult Acute Myeloid Leukemia, Adult Acute Lymphoid Leukemia, Myelodysplastic Syndrome
- Trial name
- NCT01295710
- Testing
- US-ATG-F
- Where
- 28 sites in United States, Australia
- Volunteers
- 260 people
- Sponsor
- Neovii Biotech
Carcinoma, Non-Small-Cell Lung
Phase III Trial BI 695502 Plus Chemotherapy vs. Avastin® Plus Chemotherapy in Patients With Lung Cancer
The objective of this phase III trial is to establish statistical equivalence in terms of efficacy (best overall response rate [ORR], proportion of patients with complete response [CR] plus partial response [PR]) until 18 weeks…
- Trial name
- NCT02272413
- Testing
- BI 695502, Avastin
- Where
- 189 sites in United States, Argentina and 26 more
- Volunteers
- 671 people
- Sponsor
- Boehringer Ingelheim
Locally Advanced Solid Tumors, Metastatic Solid Tumors
A Phase 1 Study of INCMGA00012 in Patients With Advanced Solid Tumors
The primary goal of this Phase 1 study is to characterize the safety and tolerability of INCMGA00012 and establish the maximum tolerated dose (MTD) of INCMGA00012 administered on either every two week or every four week schedules…
- Trial name
- NCT03059823
- Testing
- retifanlimab
- Where
- 80 sites in United States, Australia and 14 more
- Volunteers
- 325 people
- Sponsor
- Incyte Corporation
Advanced Solid Tumors, Metastatic Solid Tumors
Phase 1b Trial of BGJ398/BYL719 in Solid Tumors
To study the safety and efficacy of the combination of BGJ398 with BYL719 in patients whose tumors express mutations to PIK3CA with or without alterations to FGFR 1-3.
- Trial name
- NCT01928459
- Testing
- BGJ398, BYL719
- Where
- 22 sites in United States, Australia and 10 more
- Volunteers
- 62 people
- Sponsor
- Novartis Pharmaceuticals
Colon Cancer, Colorectal Cancer
PEAK: Panitumumab Plus mFOLFOX6 vs. Bevacizumab Plus mFOLFOX6 for First Line Treatment of Metastatic Colorectal Cancer (mCRC) Patients With Wild-Type Kirsten Rat Sarcoma-2 Virus (KRAS) Tumors
The primary objective of this study is to estimate the treatment effect on progression-free survival (PFS) of panitumumab relative to bevacizumab in combination with mFOLFOX6 chemotherapy as first-line therapy in patients with…
- Conditions
- Colon Cancer, Colorectal Cancer, Rectal Cancer, Metastatic Colorectal Cancer
- Trial name
- NCT00819780
- Testing
- Panitumumab, Bevacizumab, mFOLFOX6
- Where
- 95 sites in United States, Belgium and 4 more
- Volunteers
- 285 people
- Sponsor
- Amgen
Relapsed or Refractory Lymphoma
Clinical Study of U29 Injection (CD30-CART) in Patients With CD30-Positive Relapsed/Refractory Lymphoma
This is a single-center, open-label study conducted in subjects with relapsed or refractory CD30-positive lymphoma, with priority given to Hodgkin lymphoma and anaplastic large cell lymphoma.
- Trial name
- NCT07453446
- Testing
- CD30 CAR-T Cells
- Where
- China
- Sponsor
- Shanghai Unicar-Therapy Bio-medicine Technology Co.,Ltd
Venous Thromboembolism (VTE)
Study to Gather Information How Often Venous Thromboembolism Occurs in Prostate Cancer Patients in Sweden and How This Condition is Treated With Blood Thinners
Patients with cancer are at a significantly increased risk of experiencing a venous thromboembolism (VTE). VTE is defined by a blood clot in the leg or lower extremity (deep vein thrombosis) or a blood clot in the lung (pulmonary…
- Trial name
- PRACTISE (NCT03965741)
- Testing
- Rivaroxaban (Xarelto, BAY59-7939), Apixaban(Eliquis), Pradaxa (Dabigatran etexilate)
- Where
- Sweden
- Volunteers
- 97,765 people
- Sponsor
- Bayer
Non-hematological Malignancies
Open-label Pharmacokinetic Study of Iron Isomaltoside 1000 (Monofer®) Administered by 500 mg IV Bolus Injection or 1000 mg Intravenous Infusion to Patients With Non-hematological Malignancies Associated With Chemotherapy Induced Anaemia (CIA)
The purpose of this study is to assess the pharmakokinetic properties of higher doses (500 mg and 1000 mg) of Monofer(R)in patients suffering from non-hematological malignancies with Chemotherapy induced anaemia.
- Trial name
- PK-CIA-04 (NCT01213979)
- Testing
- 500 mg iron isomaltoside 1000, 1000 mg iron isomaltoside 1000
- Volunteers
- 16 people
- Sponsor
- Pharmacosmos A/S
Stomach Neoplasms
Study Of Sunitinib With S-1 And Cisplatin For Gastric Cancer
To assess the maximal tolerated dose (MTD) and overall safety of sunitinib when administered in combination with S-1 and Cisplatin in patients with advanced/metastatic gastric cancer.
- Trial name
- NCT00553696
- Testing
- Cisplatin, S-1, Sunitinib
- Where
- 3 sites in Japan
- Volunteers
- 27 people
- Sponsor
- Pfizer
Neoplasm Malignant
First in Man Study of SAR566658 Administered in Patients With CA6-Positive and Refractory Solid Tumor
Primary Objective: To determine the maximum tolerated dose (MTD) of SAR566658 Secondary Objectives: To characterize the safety profile of SAR566658 To evaluate the pharmacokinetic profile of SAR566658 To assess the potential…
- Trial name
- NCT01156870
- Testing
- SAR566658
- Where
- 5 sites in United States, France and 1 more
- Volunteers
- 114 people
- Sponsor
- Sanofi
Advanced Solid Tumours, Small Cell Lung Cancer
IMP4297 in Combination With Temozolomide in Patients With Advanced Solid Tumors and Small Cell Lung Cancer
This is an open-label, multi-center, dose-escalation and dose-expansion phase I study to evaluate the safety, tolerability, PK characteristics and anti-tumor activity of PARP inhibitor IMP4297 and temozolomide combination therapy…
- Trial name
- NCT04434482
- Testing
- IMP4297(senaparib)
- Where
- 21 sites in United States, Australia and 3 more
- Volunteers
- 59 people
- Sponsor
- Impact Therapeutics, Inc.
Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN), Acute Myeloid Leukemia (AML)
Tagraxofusp in Patients With Blastic Plasmacytoid Dendritic Cell Neoplasm or Acute Myeloid Leukemia
This is a 4-stage, non-randomized, open-label, dose escalation and expansion, multicenter study. A cycle of therapy is 21 days. Stage 1 was a dose-escalation stage.
- Trial name
- NCT02113982
- Testing
- Tagraxofusp
- Where
- 9 sites in United States
- Volunteers
- 138 people
- Sponsor
- Stemline Therapeutics, Inc.
Small Cell Lung Cancer
A Study of Prexasertib (LY2606368) in Participants With Extensive Stage Disease Small Cell Lung Cancer
The purpose of this study is to evaluate the safety and efficacy of prexasertib when given to participants with extensive stage disease small cell lung cancer (ED-SCLC).
- Trial name
- NCT02735980
- Testing
- Prexasertib
- Where
- 41 sites in United States, France and 8 more
- Volunteers
- 133 people
- Sponsor
- Eli Lilly and Company
Metastatic Castration Resistant Prostate Cancer (mCRPC)
EPIX, a Study to Gather More Information About Characteristics of Patients and Other Factors Which May Contribute to Survival Over a Long Period of Time in Patients With Metastatic Castration-resistant Prostate Cancer (mCRPC) Treated With Radium-223 (Xofigo)
In this observational study researchers want to gather more information about the characteristics of patients treated with Radium-223 (Xofigo) who had survived over a long period of time prostate cancer that had spread to other…
- Trial name
- EPIX (NCT04516161)
- Testing
- Radium-223 dichloride (Xofigo, BAY88-8223)
- Where
- United States
- Volunteers
- 1,180 people
- Sponsor
- Bayer
Non-Small-Cell Lung Cancer
A Study to Evaluate the Safety and Efficacy of Zoledronic Acid in the Prevention or Delaying of Bone Metastasis in Patients With Stage IIIA and IIIB Non-small Cell Lung Cancer (NSCLC)
30-40% of patients with lung cancer will develop bone metastases during the course of their disease, which can lead to pain, decreased mobility and skeletal complications.
- Trial name
- NCT00172042
- Testing
- Zoledronic acid 4 mg
- Where
- 69 sites in Belgium, China and 13 more
- Volunteers
- 437 people
- Sponsor
- Novartis Pharmaceuticals
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.